Whittier Trust Co Of Nevada Has Increased Nike Cl B (NKE) Stake By $1.34 Million; Last Week Asterias Biotherapeutics (NYSEMKT:AST) Coverage

June 20, 2017 - By Richard Conner

Among 3 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Asterias Biotherapeutics had 5 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was initiated by Chardan Capital Markets with “Buy” on Monday, May 23. FBR Capital initiated the shares of AST in report on Thursday, November 19 with “Outperform” rating. The stock has “Buy” rating by MLV on Tuesday, August 11. The stock of Asterias Biotherapeutics Inc (NYSEMKT:AST) has “Outperform” rating given on Tuesday, March 7 by FBR Capital. On Thursday, September 3 the stock rating was upgraded by Zacks to “Hold”. See Asterias Biotherapeutics Inc (NYSEMKT:AST) latest ratings:

07/03/2017 Broker: FBR Capital Rating: Outperform Old Target: $10.00 New Target: $6.00 Reinitiate

Whittier Trust Co Of Nevada Inc increased Nike Inc Cl B (NKE) stake by 42.22% reported in 2016Q4 SEC filing. Whittier Trust Co Of Nevada Inc acquired 26,760 shares as Nike Inc Cl B (NKE)’s stock declined 8.78%. The Whittier Trust Co Of Nevada Inc holds 90,141 shares with $4.58M value, up from 63,381 last quarter. Nike Inc Cl B now has $83.14 billion valuation. The stock increased 1.80% or $0.92 during the last trading session, reaching $52.02. About 128 shares traded. Nike Inc (NYSE:NKE) has declined 9.24% since June 20, 2016 and is downtrending. It has underperformed by 25.94% the S&P500.

The stock increased 6.25% or $0.2 during the last trading session, reaching $3.4. About 99,194 shares traded. Asterias Biotherapeutics Inc (NYSEMKT:AST) has risen 4.43% since June 20, 2016 and is uptrending. It has underperformed by 12.27% the S&P500.

Asterias Biotherapeutics, Inc. is a biotechnology company. The company has market cap of $159.99 million. The Firm is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. It currently has negative earnings. The Firm has over two technology platforms.

Investors sentiment increased to 0.98 in Q4 2016. Its up 0.04, from 0.94 in 2016Q3. It improved, as 84 investors sold NKE shares while 443 reduced holdings. 112 funds opened positions while 405 raised stakes. 993.29 million shares or 0.55% less from 998.81 million shares in 2016Q3 were reported. 4.99 million are held by Blue Ridge Ltd. Da Davidson And holds 0.11% in Nike Inc (NYSE:NKE) or 99,244 shares. North Star Asset Mngmt owns 52,603 shares. Orca Inv Mgmt Lc owns 34,025 shares. Wetherby Asset Mgmt Incorporated reported 31,529 shares. Payden Rygel holds 0.01% or 2,000 shares. Argi Inv Lc invested in 8,556 shares. Dynamic Management Limited owns 12,532 shares. Blackrock Inc stated it has 0.22% in Nike Inc (NYSE:NKE). Carlton Hofferkamp & Jenks Wealth Mgmt Limited Liability has invested 1.52% in Nike Inc (NYSE:NKE). Security Natl Trust reported 2,988 shares stake. Natixis Asset holds 0.08% or 17,732 shares. Gam Ag stated it has 0.35% in Nike Inc (NYSE:NKE). Great West Life Assurance Can has 2.51 million shares. 6,508 were reported by Ims Cap.

Among 39 analysts covering Nike Inc. (NYSE:NKE), 23 have Buy rating, 2 Sell and 14 Hold. Therefore 59% are positive. Nike Inc. had 137 analyst reports since July 29, 2015 according to SRatingsIntel. B. Riley & Co maintained the stock with “Neutral” rating in Wednesday, September 28 report. Telsey Advisory Group maintained the shares of NKE in report on Tuesday, September 22 with “Outperform” rating. UBS maintained Nike Inc (NYSE:NKE) on Monday, December 12 with “Buy” rating. The company was maintained on Wednesday, September 28 by Stifel Nicolaus. The firm has “Buy” rating given on Wednesday, March 23 by Jefferies. As per Wednesday, September 28, the company rating was maintained by Barclays Capital. The rating was maintained by Goldman Sachs on Wednesday, April 19 with “Buy”. Citigroup maintained Nike Inc (NYSE:NKE) rating on Wednesday, June 29. Citigroup has “Buy” rating and $61 target. As per Wednesday, December 23, the company rating was maintained by DA Davidson. The company was maintained on Thursday, March 23 by Instinet.

Since January 3, 2017, it had 1 buy, and 9 insider sales for $48.27 million activity. SPRUNK ERIC D also sold $2.78 million worth of Nike Inc (NYSE:NKE) on Friday, March 24. $10.62 million worth of Nike Inc (NYSE:NKE) was sold by Ayre David J on Monday, January 30. Shares for $7.09M were sold by Slusher John F. Another trade for 1,000 shares valued at $56,301 was made by LECHLEITER JOHN C on Friday, March 24. The insider PARKER MARK G sold 100,000 shares worth $5.29 million.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: